The role of coagulation disorders in the pathogenesis of (recurrent) ischemic stroke is uncertain. Therefore, the clinical utility of screening patients with ischemic stroke for these conditions and the therapeutic implications of a detected coagulation disorder in a patient who experienced ischemic stroke are uncertain. We reviewed the currently available data on the relationship between various inherited and acquired coagulation abnormalities (factor V Leiden and prothrombin G20210A mutations, deficiencies of protein C, protein S and anti-thrombin, hyperhomocysteinemia, the antiphospholipid syndrome and increased levels of fibrinogen) and ischemic stroke. Based on the existing evidence we discuss the usefulness of screening stroke patients for prothrombotic conditions and current recommendations regarding the optimal management of ischemic stroke patients in whom a coagulation disorder is found.

Additional Metadata
Keywords coagulation, diagnostic testing, prevention, stroke, thrombophilia, treatment
Persistent URL dx.doi.org/10.1586/ern.10.104, hdl.handle.net/1765/32800
Citation
de Lau, L., Leebeek, F.W.G., de Maat, M.P.M., Koudstaal, P.J., & Dippel, D.W.J.. (2010). Screening for coagulation disorders in patients with ischemic stroke. Expert Review of Neurotherapeutics, 10(8), 1321–1329. doi:10.1586/ern.10.104